• Recruiting

NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM

Updated: Sep 24

NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)


match

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)


This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.


Sponsor

National Cancer Institute (NCI)


ECOG-ACRIN Cancer Research Group

 

ClinicalTrials.gov Identifier: NCT02465060

Official Title: Molecular Analysis for Therapy Choice (MATCH)

First Posted: June 8, 2015

Click here for details on ClinicalTrials.gov


EAY131 / NCI MATCH Home Page - ECOG-ACRIN Cancer Research Group

 

Drug: Adavosertib

Definition of adavosertib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Afatinib

Drug: Afatinib Dimaleate

Definition of afatinib dimaleate - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Binimetinib

Definition of binimetinib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Capivasertib

Definition of capivasertib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Copanlisib

Definition of copanlisib hydrochloride - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Copanlisib Hydrochloride

Definition of copanlisib hydrochloride - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Crizotinib

Definition of crizotinib - NCI Drug Dictionary - NCI (cancer.gov)

Other: Cytology Specimen Collection Procedure

Drug: Dabrafenib

Definition of dabrafenib mesylate - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Dabrafenib Mesylate

Definition of dabrafenib mesylate - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Dasatinib

Definition of dasatinib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Defactinib

Definition of defactinib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Defactinib Hydrochloride

Drug: Erdafitinib

Definition of erdafitinib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: FGFR Inhibitor AZD4547

Definition of FGFR inhibitor AZD4547 - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Ipatasertib

Definition of ipatasertib - NCI Drug Dictionary - NCI (cancer.gov)

Other: Laboratory Biomarker Analysis

Drug: Larotrectinib

Drug: Larotrectinib Sulfate

Definition of larotrectinib sulfate - NCI Drug Dictionary - NCI (cancer.gov)

Biological: Nivolumab

Definition of nivolumab - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Osimertinib

Definition of osimertinib mesylate - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Palbociclib

Definition of palbociclib - NCI Drug Dictionary - NCI (cancer.gov)

Biological: Pertuzumab

Definition of pertuzumab - NCI Drug Dictionary - NCI (cancer.gov)

Drug: PI3K-beta Inhibitor GSK2636771

Definition of PI3K-beta inhibitor GSK2636771 - NCI Drug Dictionary - NCI (cancer.gov)

Biological: Relatlimab

Definition of relatlimab - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Sapanisertib

Definition of sapanisertib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Sunitinib Malate

Definition of sunitinib malate - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Taselisib

Definition of taselisib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Trametinib

Biological: Trastuzumab

Definition of trastuzumab - NCI Drug Dictionary - NCI (cancer.gov)

Biological: Trastuzumab Emtansine

Definition of ado trastuzumab emtansine - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Ulixertinib

Definition of ulixertinib - NCI Drug Dictionary - NCI (cancer.gov)

Drug: Vismodegib

Definition of vismodegib - NCI Drug Dictionary - NCI (cancer.gov)

 

Locations

United States, Alabama

United States, Alaska

United States, Arizona

United States, Arkansas

United States, California

United States, Colorado

United States, Connecticut

United States, Delaware

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Hawaii

United States, Idaho

United States, Illinois

United States, Indiana

United States, Iowa

United States, Kansas

United States, Kentucky

United States, Louisiana

United States, Maine

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Mississippi

United States, Missouri

United States, Montana

United States, Nebraska

United States, Nevada

United States, New Jersey

United States, New Mexico

United States, New York

United States, North Carolina

United States, North Dakota

United States, Ohio

United States, Oklahoma

United States, Oregon

United States, Pennsylvania

United States, Rhode Island

United States, South Carolina

United States, South Dakota

United States, Tennessee

United States, Texas

United States, Utah

United States, Vermont

United States, Virginia

United States, Washington

United States, West Virginia

United States, Wisconsin

United States, Wyoming

Guam

Puerto Rico

 

Other ECOG Trials



NCT04566328: Phase 3 - EAA181 / EQUATE - Testing the Use of Combination Therapy in NDMM

Click here for details


NCT03937635: Phase 3 - EAA173 / DETER-SMM - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma

Click here for details


NCT03941860: Phase 3 - EAA171 / OPTIMUM - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma

Click here for details


NCT02465060: Phase 2 - EAY131 / NCI-MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Click here for details







Posts Archive